Form 4: Zoetis Executive Roxanne Lagano Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Executive Vice President Roxanne Lagano reports the acquisition of stock options and restricted stock units in Zoetis Inc.
Summary
- Roxanne Lagano, an Executive Vice President at Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report includes the grant of 2,218 restricted stock units (RSUs) on February 19, 2025, which vest in three equal installments annually.
- Lagano also received 8,642 stock options on the same date, vesting similarly over three years.
- The filing also details existing holdings of RSUs and stock options granted in previous years.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is slightly positive due to the incentive structure.
Positives
- The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted RSUs and stock options.
Industry Context
Executive compensation through stock options and RSUs is a common practice in publicly traded companies to incentivize performance and align executive interests with shareholder value.
Comparison to Industry Standards
- Zoetis' executive compensation practices, including the use of stock options and restricted stock units, are generally in line with industry standards for large pharmaceutical and animal health companies.
- Companies like Elanco Animal Health and Merck Animal Health also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and grant sizes are likely benchmarked against peer companies to ensure competitive compensation packages.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize executive performance.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| February 8, 2022 | Date of grant for 5,377 stock options at an exercise price of $201.30. |
| February 8, 2023 | One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 6, 2024 | One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 19, 2025 | Date of grant for 2,218 restricted stock units and 8,642 stock options. |
| February 21, 2025 | Date of Form 4 filing. |
Keywords
Form 4, Zoetis, Lagano, Stock Options, Restricted Stock Units, Beneficial Ownership, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.